Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 6, 2010, Pages 955-960

  Bhutada, Pravinkumar ^a   Mundhada, Yogita ^a   Bansod, Kuldeep ^a   Ubgade, Alok ^a   Quazi, Mohsin ^a   Umathe, Sudhir ^b   Mundhada, Dharmendra ^a  

^a Agnihotri College of Pharmacy Wardha   (India)

^b RTM NAGPUR UNIVERSITY   (India)

Author keywords

Antalarmin; CRF; Forced swim test; HPA axis; Quercetin

Indexed keywords

ANTALARMIN; CORTICOTROPIN RELEASING FACTOR; DIAZEPAM; FLUOXETINE; QUERCETIN; ANTIOXIDANT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; SOCIAL INTERACTION; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; ANXIETY; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MENTAL STRESS; MOTOR ACTIVITY; SOCIAL BEHAVIOR; SWIMMING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MOTOR ACTIVITY; PYRIMIDINES; PYRROLES; QUERCETIN; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SOCIAL BEHAVIOR; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 77955056458     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.04.025     Document Type: Article

References (62)

1. Aguirre-Hernández E., González-Trujano M.E., Martínez A.L., Moreno J., Kite G., Terrazas T., et al. HPLC/MS analysis and anxiolytic-like effect of quercetin and kaempferol flavonoids from Tilia americana var. mexicana. J Ethnopharmacol 2010, 127:91-97.
2. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999, 160:1-12.
3. Bale T.L., Vale W.W. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J Neurosci 2003, 23:5295-5301.
4. Bhutada P.S., Mundhada Y.R., Bansod K.U., Umathe S.N., Kahale V.P., Dixit P.V., et al. Inhibitory influence of mecamylamine on ethanol withdrawal-induced symptoms in C57BL/6J mice. Behav Pharmacol 2010, 21:90-95.
5. Britton K.T., Lee G., Koob G.F. Corticotropin releasing factor and amphetamine exaggerate partial agonist properties of benzodiazepine antagonist Ro 15-1788 in the conflict test. Psychopharmacology (Berl) 1988, 94:306-311.
6. Britton K.T., Morgan J., Rivier J., Vale W., Koob G.F. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology (Berl) 1985, 86:170-174.
7. Carpenter L.L., Tyrka A.R., McDougle C.J., Malison R.T., Owens M.J., Nemeroff C.B., et al. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology 2004, 29:777-784.
8. Chen Y., Kong L.D., Xia X., Kung H.F., Zhang L. Behavioral and biochemical studies of total furocoumarins from seeds of Psoralea corylifolia in the forced swimming test in mice. J Ethnopharmacol 2005, 96:451-459.
9. Coskun O., Kanter M., Korkmaz A., Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmacol Res 2005, 51:117-123.
10. Filho A.W., Filho V.C., Olinger L., de Souza M.M. Quercetin: further investigation of its antinociceptive properties and mechanisms of action. Arch Pharm Res 2008, 31:713-721.
11. Formica J.V., Regelson W. Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol 1995, 33:1061-1080.
12. Gold P.W., Chrousos G.P. Clinical studies with corticotropin releasing factor: implications for the diagnosis and pathophysiology of depression, Cushing's disease, and adrenal insufficiency. Psychoneuroendocrinology 1985, 10:401-419.
13. Griebel G., Simiand J., Steinberg R., Jung M., Gullly D., Roger P., et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4 methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002, 301:333-345.
14. Grippo A.J., Gerena D., Huang J., Kumar N., Shah M., Ughreja R., et al. Social isolation induces behavioral and neuroendocrine disturbances relevant to depression in female and male prairie voles. Psychoneuroendocrinology 2007, 32:966-980.
15. Haleagrahara N., Radhakrishnan A., Lee N., Kumar P. Flavonoid quercetin protects against swimming stress-induced changes in oxidative biomarkers in the hypothalamus of rats. Eur J Pharmacol 2009, 621:46-52.
16. Harmer C.J., Reid C.B., Ray M.K., Goodwin G.M., Cowen P.J. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology (Berl) 2006, 186:18-24.
17. Henry H., Norman A. Encyclopedia of hormones. Corticotropin-releasing hormone, stress, and the immune system 2003, 325-329. Academic Press. S.E. Murray, M. Stenzel-Poore (Eds.).
18. Hsieh C.H., Li H.Y., Chen J.C. Nitric oxide and interleukin-1beta mediate noradrenergic induced corticotrophin-releasing hormone release in organotypic cultures of rat paraventricular nucleus. Neuroscience 2010, 165:1191-1202.
19. Huang H.J., Liang K.C., Chang Y.Y., Ke H.C., Lin J.Y., Hsieh-Li H.M. The interaction between acute oligomer Abeta(1-40) and stress severely impaired spatial learning and memory. Neurobiol Learn Mem 2010, 93:8-18.
20. Irwin M. Stress-induced immune suppression. Role of the autonomic nervous system. Ann N Y Acad Sci 1993, 697:203-218.
21. Jesse C.R., Bortolatto C.F., Savegnago L., Rocha J.B., Nogueira C.W. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1838-1843.
22. Jutkiewicz E.M., Wood S.K., Houshyar H., Hsin L.W., Rice K.C., Woods J.H. The effects of CRF antagonists, antalarmin, CP154, 526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) 2005, 180:215-223.
23. Kao T.K., Ou Y.C., Raung S.L., Lai C.Y., Liao S.L., Chen C.J. Inhibition of nitric oxide production by quercetin in endotoxin/cytokine-stimulated microglia. Life Sci 2010, 86:315-321.
24. Kaur R., Chopra K., Singh D. Role of alpha2 receptors in quercetin-induced behavioral despair in mice. J Med Food 2007, 10:165-168.
25. Kawabata K., Kawai Y., Terao J. Suppressive effect of quercetin on acute stress-induced hypothalamic-pituitary-adrenal axis response in Wistar rats. J Nutr Biochem 2010, 21:374-380.
26. Keeney A., Jessop D.S., Harbuz M.S., Marsden C.A., Hogg S., Blackburn-Munro R.E. Differential effects of acute and chronic social defeat stress on hypothalamic-pituitary-adrenal axis function and hippocampal serotonin release in mice. J Neuroendocrinol 2006, 18:330-338.
27. Kobayashi N., Machida T., Takahashi T.1., Takatsu H., Shinkai T., Abe K., et al. Elevation by oxidative stress and aging of hypothalamic-pituitary-adrenal activity in rats and its prevention by vitamin E. J Clin Biochem Nutr 2009, 45:207-213.
28. Kook D., Wolf A.H., Yu A.L., Neubauer A.S., Priglinger S.G., Kampik A., et al. The protective effect of quercetin against oxidative stress in the human RPE in vitro. Invest Ophthalmol Vis Sci 2008, 49:1712-1720.
29. Kumar A., Goyal R. Quercetin protects against acute immobilization stress-induced behaviors and biochemical alterations in mice. J Med Food 2008, 11:469-473.
30. Lee B.H., Jeong S.M., Lee J.H., Kim J.H., Yoon I.S., Lee J.H., et al. Quercetin inhibits the 5-hydroxytryptamine type 3 receptor-mediated ion current by interacting with pre-transmembrane domain I. Mol Cells 2005, 20:69-73.
31. Leonard B.E. The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 2005, 20(Suppl 3):S302-S306.
32. Li B., Suemaru K., Cui R., Araki H. Repeated electroconvulsive stimuli have long-lasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test. Life Sci 2007, 80:1539-1543.
33. Lowry C.A. Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. J Neuroendocrinol 2002, 14:911-923.
34. Lu J., Zheng Y.L., Luo L., Wu D.M., Sun D.X., Feng Y.J. Quercetin reverses d-galactose induced neurotoxicity in mouse brain. Behav Brain Res 2006, 171:251-260.
35. Luangaram S., Kukongviriyapan U., Pakdeechote P., Kukongviriyapan V., Pannangpetch P. Protective effects of quercetin against phenylhydrazine-induced vascular dysfunction and oxidative stress in rats. Food Chem Toxicol 2007, 45:448-455.
36. Mujahid A., Furuse M. Central administration of corticotropin-releasing factor induces tissue specific oxidative damage in chicks. Comp Biochem Physiol A Mol Integr Physiol 2008, 151:664-669.
37. Nair M.P., Mahajan S., Reynolds J.L., Aalinkeel R., Nair H., Schwartz S.A., et al. The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-K{green}β system. Clin Vacc Immun 2006, 13:319-328.
38. Nemeroff C.B., Bissette G., Akil H., Fink M. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy: corticotrophin releasing factor, beta-endorphin and somatostatin. Br J Psychiatry 1991, 158:59-63.
39. Pelleymounter M.A., Joppa M., Ling N., Foster A.C. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 2004, 25:659-666.
40. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
41. Rainnie D.G., Bergeron R., Sajdyk T.J., Patil M., Gehlert D.R., Shekhar A. Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci 2004, 24:3471-3479.
42. Reul J.M., Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol 2002, 2:23-33.
43. Romero M., Jiménez R., Hurtado B., Moreno J.M., Rodríguez-Gómez I., López-Sepúlveda R., et al. Lack of beneficial metabolic effects of quercetin in adult spontaneously hypertensive rats. Eur J Pharmacol 2010, 627:242-250.
44. Rupprecht R., Eser D., Zwanzger P., Möller H.J. GABAA receptors as targets for novel anxiolytic drugs. World J Biol Psychiatry 2006, 7:231-237.
45. Sevgi S., Ozek M., Eroglu L. L-NAME prevents anxiety-like and depression-like behavior in rats exposed to restraint stress. Methods Find Exp Clin Pharmacol 2006, 28:95-99.
46. Skorzewska A., Bidzinski A., Hamed A., Lehner M., Turzynska D., Sobolewska A., et al. The effect of CRF and alpha-helical CRF((9-41)) on rat fear responses and amino acids release in the central nucleus of the amygdala. Neuropharmacology 2009, 57:148-156.
47. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998, 20:1093-1102.
48. Spolidorio P.C., Echeverry M.B., Iyomasa M., Guimarães F.S., Del Bel E.A. Anxiolytic effects induced by inhibition of the nitric oxide-cGMP pathway in the rat dorsal hippocampus. Psychopharmacology (Berl) 2007, 195:183-192.
49. Swiergiel A.H., Leskov I.L., Dunn A.J. Effects of chronic and acute stressors and CRF on depression-like behavior in mice. Behav Brain Res 2008, 186:32-40.
50. Swiergiel A.H., Zhou Y., Dunn A.J. Effects of chronic footshock, restraint and corticotropin-releasing factor on freezing, ultrasonic vocalization and forced swim behavior in rats. Behav Brain Res 2007, 183:178-187.
51. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998, 19:162-166.
52. Todorovic C., Jahn O., Tezval H., Hippel C., Spiess J. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine. Neurosci Biobehav Rev 2005, 29:1323-1333.
53. Todorovic C., Sherrin T., Pitts M., Hippel C., Rayner M., Spiess J. Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice. Neuropsychopharmacology 2009, 34:1416-1426.
54. Tota S., Awasthi H., Kamat P.K., Nath C., Hanif K. Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 2010, 209:73-79.
55. Umathe S.N., Bhutada P.S., Dixit P.V., Jain N.S. Leuprolide: a luteinizing hormone releasing hormone agonist attenuates ethanol withdrawal syndrome and ethanol-induced locomotor sensitization in mice. Neuropeptides 2008, 42:345-353.
56. Umathe S.N., Bhutada P.S., Jain N.S., Shukla N.R., Mundhada Y.R., Dixit P.V. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice. Neuropeptides 2008, 42:399-410.
57. Umathe S.N., Dixit P.V., Wanjari M.M., Ullewar M.P. Leuprolide-a GnRH agonist-prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice. Int Immunopharmacol 2008, 8:71-79.
58. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981, 213:1394-1397.
59. Volke V., Wegener G., Bourin M., Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 2003, 140:141-147.
60. Young E.A., Altemus M., Lopez J.F., Kocsis J.H., Schatzberg A.F., DeBattista C., et al. HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology 2004, 29:1198-1204.
61. Zorrilla E.P., Valdez G.R., Nozulak J., Koob G.F., Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 2002, 952:188-199.
62. Zoumakis E., Rice K.C., Gold P.W., Chrousos G.P. Potential uses of corticotropin-releasing hormone antagonists. Ann N Y Acad Sci 2006, 1083:239-251.